melanoma

DCI researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire.

Co-leader of the DCI Melanoma Disease Group Georgia Beasley, MD, MHSc, is among 40 recipients of a Young Physician-Scientist Award from The American Society for Clinical Investigation.

A DCI-led research team has identified how melanoma tumors use estrogen signaling to trick the immune system into leaving them alone.

DCI's Melanoma (and advanced skin cancer) Disease Group expands Clinic 5-1 services to include dermatological cancer care for patients who require multidisciplinary care.

A decade since the first drug, an immunotherapy, was approved to treat metastatic melanoma, a leading clinician researcher goes head to head with melanoma brain metastasis.

Congrats to Lucy Boyce Kennedy, MD & Divya Natesan, MD (right) who each received a Conquer Cancer 2021 ASCO Annual Meeting Merit Award!

On May 14, join us for an opportunity to learn about innovative melanoma research, clinical trials, and care at Duke Cancer Institute.

A breast cancer researcher's study of estrogen action may lead to better treatments for other cancers.

Kevin Oeffinger, MD, is guest co-editor of a new book covering colorectal, lung, cervical, prostate, skin cancer, and ovarian cancer screening.

Brent Hanks, MD, PhD, was named associate director of Translational Science for the Melanoma Disease Group this month.

The research team found a signaling pathway within melanoma and other cancers that thwart the functioning of anti-PD-1 checkpoint inhibitors.

Genetic testing at Duke revealed a devastating diagnosis for a young nurse. But she feels it also may have saved her life.

April Salama, MD, director of the Melanoma Disease Group, has joined the Duke Center for Brain and Spine Metastasis at DCI as associate medical director.

Stephen Totty though he had simply pulled a pectoral muscle while moving furniture. But the soreness lingered. Then a painful “water balloon” full of blood developed.

Can research make immunotherapies work better, for more people?

Duke alumnus Ross Bierkan has long supported his alma mater. But his support of melanoma research at Duke is motivated by personal experience.

Surgical oncologist and melanoma specialist Georgia Beasley, MD, MHSc, has been named co-director of Duke Cancer Institute’s Melanoma Disease Group.

A willingness to try a clinical trial, plus his own brand of humor, are helping Tom Drew beat advanced cancer.It would be hard to find a more affable person.